

# PROGRAM

## March 22, Friday

**17:00 - 18:30 Registration and Reception**

**18:30 - 20:30 Business Meeting** (closed meeting)

## March 23, Saturday, 8:30 - 21:00

**8:30 - 8:40 Opening Address** (Toshihiko Torigoe, President of JACI)

**8:40 - 9:10 Keynote Lecture**

Chairman: Dr. Toshihiko Torigoe (Sapporo Medical University)

**Designing precision combination cancer immunotherapy targeting essential immune regulation points**

**Dr. Yutaka Kawakami** (International University of Health and Welfare)

**9:10 – 9:50 Spatial Biology of Tertiary Lymphoid Structure**

Chairman: Dr. Yutaka Kawakami (International University of Health and Welfare)

Online lecture: **Dendritic cells form and maintain tertiary lymphoid structures (TLSs) in cancer contributing to immunotherapeutic responses.**

**Drs. Raphael Mattiuz and Miriam Merad** (Icahn School of Medicine at Mount Sinai, USA)

**10:00 - 11:30 Clinical Immuno-Oncology : Combination Therapy and Biomarkers**

Chairmen: Drs. Yuki Kagoya (Keio University) and Yosuke Togashi (Okayama University)

**10:00~10:30**

Video Lecture: **Immunotherapy biomarkers for metastatic triple negative breast cancer**

**Dr. Leisha A. Emens** (President of SITC, ANKYRA Therapeutics, USA)

**10:30~11:00**

**Understanding the mechanisms of resistance to CAR-T cell therapy at the molecular level**

**Dr. Yuki Kagoya** (Keio University)

**11:00~11:30**

**Differences in PD-1 occupancy on target immune cells affect efficacy**

**Dr. Kiyoshi Yoshimura** (Showa University)

**11:45-12:45 Luncheon Seminar on Cancer Immuno-Pathology** sponsored by MDPI

and Toppan Inc. (日本語講演)

Chairman: Dr. Naoko Ohtani (Osaka Metropolitan University)

**Perspectives of histopathological analysis in cancer immunotherapy.** (in Japanese)

**Drs. Yoshihiko Hirohashi** (Sapporo Medical University) **and Rii Morimura** (Toppan Holdings Inc.)

**13:00 - 15:10 Dissecting the Tumor Microenvironment**

Chairmen: Drs. Wouter Scheper (Netherlands Cancer Institute) and Hiroyoshi Nishikawa (National Cancer Center)

**13:00~13:30**

**Contribution of tumor endothelial cells in tumor progression**

**Dr. Kyoko Hida** (Hokkaido University)

**13:30~14:00**

**Cancer-specific T cell features in the tumor microenvironment**

**Dr. Yosuke Togashi** (Okayama University)

**14:00~14:30**

**Immune-genome analysis of immunosuppressive mechanisms in the tumormicroenvironment**

**Dr. Hiroyoshi Nishikawa** (National Cancer Center Japan, Nagoya University)

**14:30~15:10**

**Functional decoding of intratumoral T cell repertoires through genetic screens**

**Dr. Wouter Scheper** (Netherlands Cancer Institute, The Netherlands)

**15:20 - 16:50 New Modalities of Cancer Immunotherapy**

Chairmen: Drs. Hiroaki Ikeda (Nagasaki University) and Tomohide Tsukahara (Sapporo Medical University)

**15:20~15:50**

Video Lecture: **Therapeutic targeting of intratumoral myeloid cells**

**Dr. Thomas Marron** (Icahn School of Medicine at Mount Sinai, USA)

**15:50~16:20**

**Development of cancer immunotherapy that overcomes tumor heterogeneity.**

**Dr. Hiroaki Ikeda** (Nagasaki University)

**16:20~16:50**

**Cell therapy using CCL19-expressing syngeneic or allogeneic mesenchymal stromal cells**

**Drs. Yuichi Iida and Mamoru Harada** (Shimane University)

### **17:00 - 17:50 Special Lecture**

Chairman: Dr. Toshihiko Torigoe (Sapporo Medical University)

**To be hot or not to be: that is the question of cancer immunology**

**Dr. Erwei Song** (Sun Yat-Sen University, Guangzhou, China)

### **18:00 - 19:30 Poster Discussion** with free drinks

### **19:30 - 21:00 Social Gathering and Meet the Experts**

**Dr. Leisha A. Emens:** Video introduction of SITC

**Dr. Erwei Song:** Introduction of Sun Yat-Sen University

**Dr. Wouter Scheper:** Introduction of Netherlands Cancer Institute

## **March 24, Sunday, 8:30 - 12:40**

### **8:30 - 9:40 Neoantigens and Cancer Vaccines**

Chairman: Dr. Shinichiro Fujii (RIKEN)

#### **8:30~9:00**

**Identification of immunogenic HLA class I and II neoantigens using surrogate immunopeptidomes and characterization of neoantigen-reactive CD4<sup>+</sup> T cell**

**Drs. Takayuki Kanaseki and Toshihiko Torigoe** (Sapporo Medical University)

#### **9:00~9:40**

Online lecture: **Interrogation of tumor-specific T Cells towards improving cancer immunotherapy**

**Dr. Matthew M. Gubin** (MD Anderson Cancer Center, USA)

### **9:45 - 10:55 Bioengineering for Cancer Immunotherapy**

Chairman: Dr. Takayuki Kanaseki (Sapporo Medical University)

#### **9:45~10:25**

Online lecture: **Spatiotemporally programming cytokine immunotherapy for cancer**

**Dr. Karl Dane Wittrup** (Massachusetts Institute of Technology, USA)

#### **10:25~10:55**

**Harnessing stem-like memory NK and CD8<sup>+</sup> T cells elicited by therapeutic vaccine, artificial adjuvant vector cells (aAVC) together with CD122-biased IL-2/anti-IL-2 Ab complex**

**Dr. Shinichiro Fujii** (RIKEN)

**11:00 - 12:40 Senescence, Metabolism, and Stress Responses in Cancer Immunity**

Chairmen: Drs. Thales Papagiannakopoulos (New York University) and Hozumi Motohashi (Tohoku University)

**11:00~11:30**

**The role of senescence-associated secretory phenotype (SASP) in modulating anti-tumor immunity in steatosis-associated liver cancer**

**Dr. Naoko Ohtani** (Osaka Metropolitan University)

**11:30~12:00**

**Supersulfides are key molecules for immune suppression in NRF2-activated cancer**

**Drs. Madoka Kawaguchi and Hozumi Motohashi** (Tohoku University)

**12:00~12:40**

**Dissecting the crosstalk of nutrient sensing, stress response signaling and immune evasion**

**Dr. Thales Papagiannakopoulos** (New York University, USA)

**12:40 - 12:45 Closing Remarks**

## Poster Session (March 23, Sat. 18:00 – 19:30)

- No. 01 Identification of naturally presented oncogenic KRAS neoepitope species by mass spectrometry**  
Yuriko Minegishi (Japanese Foundation for Cancer Research, Japan)
- No. 02 Detection of KRAS G12D G12V-derived neoepitopes from mutant KRAS cell lines using Mikros-LCMS**  
Noriko Iwamoto (Shimadzu Corporation, Technology Research Laboratory, Japan)
- No. 03 Identification of immunogenic HLA class I and II neoantigens using surrogate immunopeptidomes**  
Serina Tokita (Sapporo Medical University, Japan)
- No. 04 TCR-T therapy combined with ferroptosis inducer overcomes tumor heterogeneity that consists of escape variants.**  
Daisuke Ehara (Nagasaki university, Japan)
- No. 05 Development of T cell receptor gene-transferred T (TCR-T) cell therapy targeting carcinoembryonic antigen glypican-3**  
Kazunobu Ohnuki (EPOC, National Cancer Center, Japan)
- No. 06 Establishment of a NK cell line to evaluate cytotoxicity of cloned TCRs**  
Eiji Kobayashi (University of Toyama, Japan)
- No. 07 Development of allogeneic CAR-T cells with reduced immunogenicity**  
Chisato Umehara (Keio University, Japan)
- No. 08 Application of EPHB4 targeting chimeric antigen receptor T cell (CAR-T) therapy for oral squamous cell carcinoma**  
Masaya Kinjo (Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Japan)
- No. 09 Cancer cell derived blood EVs are potential predictive biomarkers for NSCLC patients treated with anti-PD-1 antibody**  
Shigeki Ohta (International University of Health and Welfare, Japan)
- No. 10 refmAb-Q nSMOL, a multiplexed and universal LC-MS/MS assay platform for therapeutic antibody quantitation**  
Takashi Shimada (Technology Research Laboratory, Shimadzu Corporation, Japan)

- No. 11 Tumor antigen-reactive CD8+ T cell population in tumor-infiltrating lymphocytes associate with better prognosis in gastric cancer**  
Nobuo Tsukamoto (Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Japan)
- No. 12 Alternation of anti-tumor responses and PD-L1 blockade effects in the squamous cell carcinoma cell-inoculated aged mouse model**  
Chenyang Zhang (Tokyo Medical and Dental University (TMDU), Japan)
- No. 13 Tumor-promoting interactome/network analysis during their progression of MASLD/MASH-associated liver cancer model**  
Yoshiki Nonaka (Osaka Metropolitan University, Japan)
- No. 14 A latent role of Sipa1 deficient mesenchymal stroma cells revealed in tumor resistant.**  
Kentaro Sumida (Medical Innovation Center, Graduate School of Medicine, Kyoto University, Japan)
- No. 15 Identification of the origin of Amomi semen species with NK cell immunomodulatory activities**  
Yoshimasa Yamamoto (University of Toyama, Japan)
- No. 16 Investigation the association between tumor cells and macrophages by the tissue section-based transcriptomics analysis for metastatic lung tissue of MMTV-PyMT mice**  
Tadashi Imafuku (Wakayama Medical University, Japan)
- No. 17 Development of 3D stromal tissue model for in vitro evaluating the behavior of immune cells.**  
Rii Morimura (TOPPAN Holdings Inc., Japan)
- No. 18 CD8 TILs acquire tissue-resident memory characteristics within distinct tumor microenvironment**  
Kosuke Kitahata (RIKEN Center for Investigative Medical Science, Japan)
- No. 19 Personal immune profiles of oral tongue squamous cell carcinoma -Part 1: Analyses of 87 cases of surgical specimens and immune subtype classification-**  
Yuya Su (Tokyo Medical and Dental University, Japan)
- No. 20 Personal immune profiles -Part 2: Analyses of the patients treated with PD-1 immune checkpoint inhibitors-**  
Ryo Ouchi (Tokyo Medical and Dental University and Toyama University, Japan)
- No. 21 Impact of surgery on outcome under systemic therapy in advance hepatocellular carcinoma**  
Shinji Itoh (Kyushu University, Japan)